IDH1 and glioblastoma: Besides that, ROC analysis was used to validate model performance in predicting IDH-wild-type GBM survival rates at 1, 2, and 3 years in entire set (0.709,0.645 and 0.694), training set (0.707,0.680 and 0.787), and validation set (0.716,0.638 and 0.617) (Figures 3G–I).